Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 study will evalu …

Category: Dementia